NVONOVO NORDISK A S

NYSE novonordisk.com


$ 128.75 $ 1.35 (1.06 %)    

Thursday, 09-May-2024 15:12:20 EDT
QQQ $ 441.05 $ 0.59 (0.13 %)
DIA $ 393.85 $ 3.78 (0.97 %)
SPY $ 519.74 $ 2.26 (0.44 %)
TLT $ 90.68 $ 0.64 (0.71 %)
GLD $ 216.24 $ 1.54 (0.72 %)
$ 126.69
$ 127.40
$ 127.00 x 200
$ 128.76 x 100
$ 127.17 - $ 128.78
$ 74.66 - $ 137.29
4,060,256
na
571,372
$ 0.64
$ 0.00
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ozempic-ftw-elon-musk-touts-novo-nordisks-blockbuster-drug-as-solution-to-childhood-obesity-problem

This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was a...

 wage-growth-slows--stock-market-celebrates-five-real-reasons-apple-is-running-up

To gain an edge, this is what you need to know today.

 job-market-cools-in-april-payrolls-miss-forecasts-wages-rise-less-than-expected-updated

U.S. labor market misses April expectations, signaling slower economic growth and potential interest rate cuts. Stocks rise, Tr...

 weight-loss-competition-heats-up-in-britain-online-pharmacies-slash-prices-for-wegovy-and-mounjaro

Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro s...

 demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-competition

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...

 novo-nordisk-updates-2024-outlook-now-expects-sales-growth-of-19-27-prior-18-26-and-operating-profit-growth-of-22-30-prior-21-29

Sales growth is now expected to be 19% to 27% at CER. Given the current exchange rates versus the Danish krone, sales growth re...

 novo-nordisk-q1-2024-gaap-eps-dkk-568-beats-dkk-515-estimate-sales-dkk-65349b-beat-dkk-63229b-estimate

Novo Nordisk (NYSE:NVO) reported quarterly earnings of DKK 5.68 per share which beat the analyst consensus estimate of DKK 5.15...

 federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-companies-like-novo-nordisk-astrazeneca

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, a...

 setback-for-novo-nordisk-denmark-shifts-prescription-guidelines-favoring-cost-effective-alternatives-for-ozempic

The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug wi...

 fda-says-novo-nordisks-wegovy-injection-17-mg75-ml-ndc-0169-4517-14-is-available

- Reuters

 fda-says-novos-wegovy-injection-25-mg5-ml-ndc-0169-4525-14-under-limited-availability-with-estimated-shortage-duration-tbd-wegovy-injection-5-mg5-ml-ndc-0169-4505-14-under-limited-availability-with-estimated-shortage-duration-tbd-wegovy-injection-1-mg5-ml-ndc-0169-4501-14-limited-availability-with-estimated-shortage-duration-tbd

- Reuters

 what-are-pricing-strategies-for-ozempic-and-wegovy-with-potential-medicare-coverage-expansion-senate-committee-questions-novo-nordisk

Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on prici...

Core News & Articles

https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1 

 changing-frugal-eating-habits---how-novo-nordiskeli-lillys-weight-loss-drugs-reshaping-food-spending

Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound g...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION